N6-methyladenosine in Gut Microbiota and Gastrointestinal Cancer: A Survey

Abstract

N6-methyladenosine (m6A) is a prevalent RNA modification that plays a critical role in gene expression regulation and metabolic processes, with profound implications for gastrointestinal cancer and gut microbiota interactions. This survey examines the multifaceted functions of m6A, orchestrated by 'writers', 'erasers', and 'readers', in RNA biology, emphasizing its influence on mRNA stability, splicing, and translation. The dynamic nature of m6A modifications facilitates cellular adaptation to environmental stimuli and underscores its significance in cancer progression and potential as a therapeutic target. The interplay between m6A and gut microbiota is pivotal in gastrointestinal cancer, as m6A modulates immune responses and metabolic pathways, influencing cancer pathogenesis through microbial interactions. Dysbiosis-induced inflammation further highlights the role of m6A in tumorigenesis. Additionally, m6A's regulatory capacity in cancer metabolism, impacting glucose and amino acid pathways, supports cancer cell proliferation and survival. The therapeutic potential of targeting m6A modifications is underscored by their dual role in oncogenesis, offering novel intervention strategies. Future research should focus on elucidating m6A's regulatory mechanisms across biological systems, leveraging advanced detection methods to explore its functional roles and therapeutic applications. Understanding m6A's interactions with pathogens presents further research opportunities, providing insights into cancer and disease interventions.

1 Introduction

1.1 Significance of m6A in RNA Modifications

N6-methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotic messenger RNA (mRNA), playing a crucial role in gene expression regulation and various cellular processes. This modification is facilitated by methyltransferase complexes, known as "writers" (e.g., METTL3, METTL14, WTAP), while demethylases such as FTO and ALKBH5, referred to as "erasers," remove it. Specific binding proteins, termed "readers," recognize m6A, mediating its involvement in essential biological functions, including RNA metabolism and cellular fate determination [1, 2]. m6A is integral to post-transcriptional regulation, influencing RNA stability, structural dynamics, and protein interactions. Its dynamic nature underscores its critical role in mRNA maturation, translation, and decay.

The m6A regulatory network comprises 'writers', 'erasers', and 'readers'. Methyltransferase complexes ('writers') catalyze m6A addition to RNA, affecting RNA stability, splicing, and translation efficiency [3]. 'Erasers', like FTO, remove m6A marks, allowing reversible regulation of RNA function [4]. 'Readers' bind to m6A-modified RNA, mediating downstream effects such as mRNA degradation or translation initiation, which are vital for cellular homeostasis [5].

The significance of m6A extends into metabolic regulation and cancer progression [6]. This modification influences drug resistance by altering gene expression and protein function, underscoring its



Figure 1: chapter structure

potential as a therapeutic target [3]. Elucidating the multifaceted roles of m6A in RNA modifications is essential for understanding its broader implications in health and disease, particularly in cancer pathogenesis [7].

1.2 Connection between m6A, Gut Microbiota, and Gastrointestinal Cancer

The interplay between m6A modifications and gut microbiota is pivotal in gastrointestinal cancer pathogenesis, offering insights into novel therapeutic strategies. m6A, a dynamic RNA modification, regulates gene expression and RNA metabolism, impacting cancer progression and immune responses. The gut microbiota, a diverse microbial community in the gastrointestinal tract, significantly influences host health, with dysbiosis associated with diseases, including cancer [7].

m6A modifications modulate gene expression related to immune regulation and metabolic pathways, essential for gut homeostasis and preventing dysbiosis. Dysbiosis, characterized by an imbalance in gut microbiota, can lead to chronic inflammation, altering the tumor microenvironment by disrupting cellular signaling pathways (e.g., WNT/beta-catenin), promoting tumorigenesis in cancers such as colorectal cancer and hepatocellular carcinoma. Additionally, microbiota-derived metabolites and the interaction between gut microbiota and microRNAs further influence these processes, emphasizing gut microbiota's complex role in cancer biology and overall health [8, 9]. Moreover, m6A impacts the interactions between gut microbiota and host cells, potentially altering microbial composition and metabolic outputs critical for cancer development.

In gastrointestinal cancer, m6A regulates essential processes such as cell proliferation, apoptosis, and metastasis by modulating oncogene and tumor suppressor gene expression. This regulation occurs through methyltransferases adding m6A to mRNA and demethylases removing it, thereby influencing RNA metabolism processes like translation, degradation, and splicing. Alterations in m6A levels are implicated in cancer pathogenesis, highlighting its significance in tumor development and progression [10, 11, 2]. This regulatory capacity positions m6A modifications as potential therapeutic targets, offering new intervention avenues by modulating gut microbiota interactions and their downstream effects on cancer biology.

1.3 Objectives and Structure of the Survey

This survey aims to elucidate the physiological functions of m6A modification and its regulatory proteins—writers, erasers, and readers—with a focus on their implications in various cancers. Key objectives include exploring RNA modifications' roles in cancer and addressing knowledge gaps re-

garding their expression, function, and molecular mechanisms. The survey provides a comprehensive overview of recent advancements in understanding m6A RNA methylation's biological functions and its significant implications for human cancer, categorizing research into distinct biological processes such as gene expression regulation, cellular metabolism, and tumor progression, while highlighting the roles of m6A methyltransferases, demethylases, and binding proteins in these processes and their associations with different cancer types [10, 2, 1, 12, 11].

The paper's structure is designed to offer a thorough overview of current m6A modification understanding. It begins with the significance of m6A in RNA modifications, followed by an exploration of its connection with gut microbiota and gastrointestinal cancer. The background section delves into key concepts like epitranscriptomics and metabolic regulation. Subsequent sections discuss m6A's role in epitranscriptomics, its impact on gut microbiota interactions, and its influence on cancer metabolism. The paper concludes by examining the therapeutic potential of targeting m6A modifications in cancer treatment and identifying future research directions [13].The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Epitranscriptomics and Its Biological Implications

Epitranscriptomics explores RNA modifications and their impact on post-transcriptional gene regulation, with N6-methyladenosine (m6A) being a key modulator of gene expression and RNA metabolism [7, 14]. This field examines various RNA chemical modifications, like m6A, which are crucial for regulating both mRNA and noncoding RNAs, influencing cellular processes and disease mechanisms. m6A affects RNA stability and protein interactions, impacting transcription, processing, splicing, degradation, and translation, thereby modulating cellular responses to stimuli. The framework of epitranscriptomics involves RNA-binding proteins categorized as 'writers', 'readers', and 'erasers', essential for dynamic RNA modification regulation. Advances in detection methods, particularly next-generation sequencing and enhanced bioinformatics, have refined our understanding of RNA modifications, allowing precise categorization of m6A, pseudouridine (), and 5-methylcytosine (m5C) based on their distinct structures and functions in gene expression regulation and cellular signaling pathways [15, 16]. This progress expands our knowledge of the epitranscriptome's complex landscape, influencing RNA stability, localization, and interactions, thus enhancing our understanding of fundamental biological processes and disease mechanisms.

2.2 Gut Microbiota and Its Interaction with Host

The gut microbiota, a diverse microbial community in the gastrointestinal tract, plays a vital role in host health through interactions with organs such as the brain, liver, and lungs [8]. These interactions are crucial for physiological processes like digestion, immune modulation, and metabolic regulation. Dysbiosis, or microbial imbalance, is associated with diseases like cancer and metabolic disorders, emphasizing the gut microbiota's role in health and disease [8]. Recent advances in epigenetic and epitranscriptomic research reveal how gut microbiota influences host gene expression, with viruses exploiting these processes to regulate gene expression and evade host immune responses [17]. This interplay highlights potential therapeutic interventions targeting microbial communities or their interactions with the host epitranscriptome. Understanding RNA modifications, especially in neural processes, opens new avenues for exploring therapeutic potentials in gut microbiota interactions [18]. Limitations in high-throughput methods, such as MERIP and m6A-seq, challenge accurate m6A site identification, crucial for understanding microbial influence on host gene expression [14]. The gut microbiota-host interaction is a complex, evolving process critical for various physiological systems, with significant implications for disease mechanisms. Gut microbiota-derived metabolites, like short-chain fatty acids, influence cell signaling pathways linked to conditions such as colorectal cancer and vascular dysfunction. The interplay between gut microbiota and microRNAs is vital for regulating gene expression and disease development, highlighting potential innovative therapeutic strategies in precision medicine [8, 19].

2.3 Gastrointestinal Cancer and Metabolic Regulation

Gastrointestinal cancer presents a significant health challenge, characterized by complex etiology and multifaceted progression mechanisms [20]. A critical aspect of cancer progression is the reprogramming of cellular metabolism, particularly amino acid metabolism, essential for tumor growth and survival [21]. This metabolic reprogramming supports rapid cancer cell proliferation by altering nutrient uptake and utilization to meet the biosynthetic and energetic demands of tumorigenesis. Epitranscriptomic modifications, such as m6A, are pivotal in regulating metabolic pathways crucial for cancer cell survival and proliferation [13]. m6A modifications influence gene expression by modulating RNA stability, splicing, and translation, impacting key metabolic processes [22]. The dynamic regulation of m6A methylation and demethylation processes affects the expression of genes involved in metabolic pathways, contributing to the metabolic flexibility observed in cancer cells [3]. The interaction between epithelial-mesenchymal transition (EMT) factors and metabolic pathways underscores the complexity of cancer progression. EMT facilitates metastasis and enhances cancer cell invasiveness [6]. This transition is intricately linked to metabolic reprogramming, as changes in energy metabolism can influence EMT and vice versa, highlighting the interplay between these processes in cancer progression. Environmental factors, such as benzo[a]pyrene and bisphenol A, can modulate RNA modifications, potentially altering cancer metabolism and contributing to disease progression [7]. Understanding these external influences on metabolic regulation is crucial for cancer biology.

In recent years, the significance of N6-methyladenosine (m6A) modifications in epitranscriptomics has garnered considerable attention. These modifications play a pivotal role in various biological processes, influencing RNA metabolism and cellular functions. To elucidate the complex interplay of m6A modifications, we present a comprehensive overview of its hierarchical structure. As illustrated in Figure 2, this figure categorizes the mechanisms of m6A modification, delineating the distinct roles of writers, erasers, and readers. Each category is further subdivided into specific components, effectively highlighting their functions and contributions to RNA metabolism and cellular processes. This structured representation not only enhances our understanding of m6A's multifaceted role but also underscores its biological implications, providing a clear framework for future research in the field.



Figure 2: This figure shows the hierarchical structure of the role of m6A in epitranscriptomics, categorizing the mechanisms of m6A modification, the roles of writers, erasers, and readers, and the biological implications of m6A modifications. Each category is further divided into specific components, highlighting their functions and contributions to RNA metabolism and cellular processes.

3 Role of m6A in Epitranscriptomics

3.1 Mechanisms of m6A Modification

N6-methyladenosine (m6A) modification in RNA is orchestrated by a triad of proteins known as 'writers', 'erasers', and 'readers'. The 'writers', primarily the METTL3-METTL14 methyltransferase complex, catalyze the methylation of adenosine residues, thereby modulating mRNA stability and translation efficiency [23]. Co-factors like WTAP enhance the specificity of this complex. 'Erasers', such as FTO and ALKBH5, demethylate m6A, allowing reversible RNA regulation, crucial for environmental signal adaptation, as demonstrated in heat shock protein (HSP) transcript regulation under stress [4, 2]. 'Readers', including YTH domain-containing proteins, recognize m6A-modified RNA, influencing splicing, export, degradation, and translation [5]. These interactions modify RNA secondary structure and cellular localization, highlighting the intricate regulation of RNA biology [24]. Advances in detection, such as m6A-sensitive RNA-cleaving deoxyribozymes, have illuminated m6A's distribution and its roles in viral and host-pathogen interactions. Integrating thermodynamic principles into RNA predictions has elucidated how m6A affects RNA dynamics and protein interactions, revealing both stabilizing and destabilizing effects depending on its position [25, 24].

3.2 Roles of Writers, Erasers, and Readers

The regulation of m6A modifications involves a complex interplay among 'writers', 'erasers', and 'readers', each crucial for RNA function and stability. The METTL3-METTL14 complex, aided by auxiliary proteins like WTAP, marks RNA with m6A, essential for mRNA stability, splicing, and translation [26]. 'Erasers' such as FTO and ALKBH5 remove these marks, enabling a reversible modification cycle that fine-tunes gene expression in response to environmental cues [26], vital for cellular homeostasis and stress response [27]. 'Readers', including YTHDF1, YTHDF2, and YTHDC1, mediate downstream effects of m6A, influencing RNA metabolism [26]. YTHDF2, for instance, promotes mRNA degradation, while YTHDC1 aids mRNA export, illustrating the complexity of m6A-mediated regulation [23].

This complexity is further illustrated in Figure 3, which depicts the hierarchical structure of m6A regulation in RNA, categorizing the roles of writers, erasers, and readers, and highlighting their contributions to RNA metabolism and gene expression. These interactions impact broader biological processes, including plant growth and disease mechanisms. Understanding m6A's regulatory roles offers insights into gene expression networks and potential therapeutic targets in diseases linked to dysregulated RNA methylation [15, 11, 18].



Figure 3: This figure illustrates the hierarchical structure of m6A regulation in RNA, categorizing the roles of writers, erasers, and readers, and highlighting their contributions to RNA metabolism and gene expression.

3.3 Biological Implications of m6A Modifications

m6A modifications are crucial regulatory elements in cellular processes, significantly impacting RNA metabolism and stability. They influence mRNA stability, localization, and translation, essential for gene expression regulation, particularly under stress [28]. Their dynamic nature allows rapid cellular responses to environmental stimuli, maintaining cellular homeostasis. In cancer biology,

m6A modifications regulate oncogenes and tumor suppressors, affecting cancer progression and metastasis [2]. m6A's ability to modulate RNA stability and translation is vital for cancer cells' adaptation to metabolic demands. 'Readers' like YTHDC1 and YTHDF2 mediate m6A effects, with YTHDC1 influencing mRNA export and YTHDF2 facilitating mRNA degradation, crucial for gene expression regulation [23, 5]. Predictive tools like M6AMRFS have enhanced m6A site identification across species, providing insights into RNA metabolism and evolutionary conservation [14]. These advancements deepen our understanding of m6A's biological implications, offering new perspectives on gene regulation and potential therapeutic applications in diseases with dysregulated RNA methylation.

4 Gut Microbiota and Gastrointestinal Cancer

4.1 The Role of Gut Microbiota in Cancer Development

The gut microbiota, comprising a diverse microbial community within the gastrointestinal tract, plays a critical role in host health and the pathogenesis of gastrointestinal cancer [8]. Interactions between the microbiota and the host immune system are fundamental in modulating immune responses that influence cancer development. Dysbiosis, or microbial imbalance, can induce chronic inflammation, a known cancer risk factor [8].

Recent studies highlight the influence of RNA modifications, particularly N6-methyladenosine (m6A), on the interplay between gut microbiota and host cells, affecting cancer progression [29]. m6A modifications regulate immune cell behavior and the inflammatory milieu within the gastrointestinal tract, crucial for cancer development [26]. Viral interactions with the host epitranscriptome, such as m6A/m6Am modifications in Kaposi's sarcoma-associated herpesvirus, illustrate pathways involved in tumorigenesis [30]. These insights suggest potential therapeutic strategies targeting RNA modifications and microbiota interactions for cancer treatment [8].

The relationship between gut microbiota and gastrointestinal cancer involves complex interactions with host immune responses and RNA modifications influencing key signaling pathways, such as WNT/beta-catenin in colorectal cancer and T cell receptor signaling. Microbiota-derived metabolites, like butyrate, and microRNAs are pivotal in these processes, linking gut microbiota to cancer progression and host physiology [8, 31]. Understanding these interactions offers promising avenues for therapeutic interventions targeting gut microbiota's impact on cancer progression.

4.2 m6A RNA Methylation and its Impact on Gut Microbiota Interactions

N6-methyladenosine (m6A) RNA methylation is crucial for modulating interactions between gut microbiota and host cells, significantly affecting gastrointestinal cancer. The dynamic nature of m6A modifications regulates gene expression and RNA metabolism, influencing host-pathogen interactions and immune responses [32]. The m6A regulatory network, involving 'writers', 'erasers', and 'readers', is vital for understanding the complex interactions between gut microbiota and host cells [7].

m6A modifications are particularly relevant for mRNA export mechanisms, affecting cellular localization and availability of mRNAs involved in immune regulation [23]. FTO-mediated m6A modifications in small nuclear RNAs can alter splicing patterns, potentially impacting cancer development through modified RNA-protein interactions [4].

Advancements in machine learning, such as M6AMRFS, enhance the identification of m6A sites, improving our understanding of how these modifications influence gut microbiota interactions [14]. Integrating m6A site context into predictive models enhances insights into mRNA decay mechanisms, crucial for maintaining RNA stability and function [5].

m6A modifications serve as a critical regulatory mechanism in RNA metabolism, influencing biological processes including gut microbiota interactions, immune response regulation, and cancer progression. This modification is regulated by a complex interplay of methyltransferases (the "writers"), demethylases (the "erasers"), and m6A-binding proteins (the "readers"), which collectively shape gene expression patterns and cellular behaviors. As research continues to elucidate the extensive roles of m6A in health and disease, its potential as a target for therapeutic interventions in cancer

and immune-related disorders becomes increasingly apparent [12, 11, 2]. The therapeutic potential of targeting m6A modifications in gastrointestinal cancer treatment is progressively gaining recognition.

5 m6A and Cancer Metabolism

The intricate relationship between N6-methyladenosine (m6A) modifications and cancer metabolism has become a focal point in cancer research, revealing m6A's pivotal roles in regulating metabolic pathways crucial for cancer cell proliferation and survival. By elucidating these roles, researchers aim to uncover new therapeutic strategies targeting metabolic reprogramming in cancer. This section explores m6A's specific influence on metabolic pathways, gene expression, and broader cancer biology implications.

5.1 m6A's Role in Metabolic Pathways

m6A modifications are essential in modulating metabolic pathways in cancer cells, impacting glucose, lipid, and amino acid metabolism to meet the biosynthetic and energetic needs of tumors [10]. The dynamic regulation of gene expression by m6A allows cancer cells to maintain metabolic flexibility. Amino acids, as energy sources and biosynthetic precursors, are critical for tumor growth, with m6A influencing their metabolism to ensure nutrient availability [21, 6].

The role of m6A in RNA stability and translation is exemplified by YTHDC2, an m6A 'reader', which enhances translation efficiency of m6A-marked mRNAs, impacting metabolic pathways vital for germ cell development and cancer progression [33]. YTHDF proteins, as potential biomarkers and therapeutic targets, influence tumor behavior by regulating these pathways [34].

Advancements in molecular simulations have highlighted the importance of accurate m6A force-field parameters in reproducing binding free energies, offering insights into m6A-mediated cancer metabolism regulation. This integration of experimental and predictive models enhances our understanding of m6A's role in cancer biology [16].

5.2 Regulatory Mechanisms of m6A in Cancer Metabolism

m6A's regulatory mechanisms in cancer metabolism involve dynamic RNA modifications that affect key metabolic pathways necessary for tumor growth and survival. m6A RNA methylation modulates gene expression in metabolic processes, facilitating cancer cells' metabolic reprogramming to adapt to their microenvironment [10]. The reversible methylation of snRNAs by FTO, an m6A 'eraser', underscores m6A's role in RNA splicing and metabolic regulation [4, 22].

The interaction between m6A modifications and RNA-binding proteins ('readers') further illustrates the complexity of m6A-mediated regulation, influencing RNA stability, localization, and translation efficiency. This regulatory network, comprising methyltransferases ('writers'), demethylases ('erasers'), and m6A-binding proteins ('readers'), modulates gene expression through RNA metabolism stages, impacting tumor-related genes and cancer stem cell properties [35, 11, 2].

m6A RNA methylation's regulatory mechanisms in cancer metabolism highlight the critical role of RNA modifications in enabling cancer cells to adapt their metabolic pathways. This adaptation, facilitated by m6A's involvement in RNA transcription, maturation, translation, and degradation, allows cancer cells to efficiently respond to growth-promoting signals [11, 10]. Understanding these mechanisms is crucial for developing targeted therapies to disrupt tumors' metabolic dependencies.

As shown in Figure 4, the expanding research on m6A methylation and cancer metabolism reveals the complex regulatory mechanisms underlying cancerous transformations. The diagrams illustrate m6A's roles in metabolic pathways and gene regulation. The first diagram maps metabolic pathways, emphasizing nutrient and metabolite flow, particularly the TCA cycle, crucial for cellular energy. The second image displays a network of proteins and molecules in gene regulation, highlighting the nucleus's central role. The final image focuses on the m6A methylation mechanism, detailing the involvement of writer complexes, reader proteins, and demethylases like FTO or ALKBH5. These visuals provide a comprehensive overview of how m6A modifications influence cancer metabolism by altering gene expression and metabolic pathways, offering insights into novel cancer therapies [21, 12, 11].



(a) The image depicts a metabolic pathway diagram illustrating the flow of nutrients and metabolites within a cell.[21]



(b) The image depicts a complex network of proteins and molecules involved in gene regulation and transcription.[12]



(c) The m6A methylation mechanism[11]

Figure 4: Examples of Regulatory Mechanisms of m6A in Cancer Metabolism

6 Implications for Research and Therapy

6.1 Therapeutic Implications of Targeting m6A Modifications

Targeting N6-methyladenosine (m6A) modifications holds significant promise for cancer therapy, as these modifications regulate gene expression involved in cancer progression, including processes such as self-renewal, differentiation, invasion, and apoptosis. This regulation is mediated by a complex interplay of 'writer' methyltransferases, 'eraser' demethylases, and 'reader' proteins, which can either promote or inhibit oncogenic processes [10, 12, 11, 2]. Therapeutic strategies that manipulate m6A pathways could disrupt tumor growth and metastasis effectively.

FTO, an m6A 'eraser', has emerged as a promising therapeutic target due to its influence on snRNA methylation, which affects RNA splicing patterns and gene expression, impacting cancer cell metabolism and proliferation [4]. Additionally, computational tools like M6AMRFS have advanced the understanding of m6A site functionality, facilitating the identification of critical regulatory sites for intervention [14].

YTH domain-containing proteins, such as YTHDC2, YTHDF1, YTHDF2, and YTHDC1, interact with m6A-modified RNAs to regulate essential cellular processes like spermatocyte development, mRNA stability, translation, and nuclear export. Their roles in mRNA metabolism position them as potential therapeutic targets for reproductive health issues and other cellular dysfunctions [33, 23, 5]. However, challenges persist in understanding YTHDFs' interactions with m6A-modified RNAs and their variable functional outcomes, necessitating further research to fully harness their therapeutic potential.

The pivotal role of m6A modifications in cancer biology underscores their potential as therapeutic targets, particularly in enhancing chemotherapy and immunotherapy efficacy. Evidence indicates that m6A modifications influence gene expression and regulate key processes involved in tumor progression and therapeutic responses [11, 2]. Continued research is crucial for developing targeted therapies that disrupt the metabolic and regulatory networks essential for cancer progression.

6.2 Future Directions and Emerging Trends

Future research on N6-methyladenosine (m6A) aims to deepen the understanding of its role in cancer biology and therapy. A primary focus is elucidating m6A's regulatory mechanisms across diverse biological systems, particularly in cancer and developmental biology [13]. Advancements in detection techniques will be vital for uncovering the functional roles of various RNA modifications, enhancing comprehension of their biological contexts and therapeutic applications [18].

Emerging trends highlight the interplay between m6A modifications and metabolic pathways, especially regarding epithelial-mesenchymal transition (EMT) in various cancers, suggesting potential for novel therapeutic interventions [6]. Additionally, the dynamic roles of epitranscriptomic modifications in drug resistance warrant further investigation, emphasizing the need for advanced technologies to explore these interactions [3].

Investigating m6A's specific roles in different contexts, including its manipulation by pathogens, presents a promising research avenue. Understanding these interactions could inform therapeutic strategies for cancer and other diseases [32]. Exploring FTO-mediated methylation dynamics in broader cellular contexts will elucidate its implications for cancer and metabolic disorders [4].

Future studies should also examine the implications of m6A modification on alternative splicing and other RNA processing events, as these processes are integral to gene expression regulation [23]. Expanding datasets and exploring additional RNA-binding proteins involved in m6A-mediated degradation will enhance understanding of m6A's role in RNA stability and function [5].

These research directions underscore m6A modifications' critical significance in cancer biology, revealing their influence on cellular processes such as gene expression, differentiation, and apoptosis. Insights into m6A's regulatory mechanisms, involving a complex interplay of methyltransferases (writers), demethylases (erasers), and m6A-binding proteins (readers), suggest that targeting these pathways could lead to innovative therapeutic strategies, transforming cancer treatment and improving patient outcomes by addressing the molecular mechanisms underlying tumor progression [11, 2].

7 Conclusion

This survey highlights the pivotal role of N6-methyladenosine (m6A) in regulating gene expression, underscoring its profound implications for gastrointestinal cancer and its interactions with gut microbiota. m6A, a crucial RNA modification, influences cellular processes such as RNA stability, splicing, and translation, which are vital for maintaining cellular equilibrium and adapting to environmental changes. Its dynamic nature allows for precise modulation of gene expression in response to metabolic signals, marking its importance in cancer biology and its potential as a therapeutic target.

The interplay between m6A modifications and gut microbiota is particularly noteworthy, as it affects cancer progression by modulating immune responses and metabolic pathways. An imbalance in gut microbiota, or dysbiosis, can lead to chronic inflammation, creating a microenvironment conducive to tumor development. m6A modifications play a crucial role in managing the interactions between gut microbiota and host cells, potentially influencing microbial composition and metabolic outputs that are critical to cancer progression.

Research into m6A's regulatory roles in cancer metabolism reveals its impact on essential metabolic pathways, such as those involving glucose and amino acids, which are crucial for tumor growth and survival. The dual role of m6A modifications in both promoting and inhibiting oncogenic processes underscores their potential as targets for innovative cancer therapies.

Future investigations should focus on deciphering the regulatory mechanisms of m6A across different biological systems, especially in the context of cancer and developmental biology. Advanced detection methods will be crucial to uncovering the functional roles of various RNA modifications, thereby expanding our understanding of their biological significance and therapeutic potential. Additionally, exploring the specific roles of m6A in diverse contexts, including its manipulation by pathogens, presents promising research opportunities that could provide valuable insights into therapeutic strategies for cancer and other diseases.

References

[1] Zhi-Man Zhu, Fu-Chun Huo, and Dong-Sheng Pei. Function and evolution of rna n6-methyladenosine modification. *International journal of biological sciences*, 16(11):1929, 2020.

[2] Tianyi Wang, Shan Kong, Mei Tao, and Shaoqing Ju. The potential role of rna n6-methyladenosine in cancer progression. *Molecular cancer*, 19:1–18, 2020.

[3] pitranscriptomics and epiproteom.

[4] Jan Mauer, Miriam Sindelar, Vladimir Despic, Théo Guez, Ben R Hawley, Jean-Jacques Vasseur, Andrea Rentmeister, Steven S Gross, Livio Pellizzoni, Françoise Debart, et al. Fto controls reversible m6am rna methylation during snrna biogenesis. *Nature chemical biology*, 15(4):340–347, 2019.

[5] Ting-He Zhang, Sumin Jo, Michelle Zhang, Kai Wang, Shou-Jiang Gao, and Yufei Huang. Understanding ythdf2-mediated mrna degradation by m6a-bert-deg, 2024.

[6] Ilias Georgakopoulos-Soares, Dionysios V Chartoumpekis, Venetsana Kyriazopoulou, and Apostolos Zaravinos. Emt factors and metabolic pathways in cancer. *Frontiers in oncology*, 10:499, 2020.

[7] Akin Cayir, Hyang-Min Byun, and Timothy M Barrow. Environmental epitranscriptomics. *Environmental Research*, 189:109885, 2020.

[8] Qingqing Feng, Wei-Dong Chen, and Yan-Dong Wang. Gut microbiota: an integral moderator in health and disease. *Frontiers in microbiology*, 9:151, 2018.

[9] Irina Primac, Audrey Penning, and François Fuks. Cancer epitranscriptomics in a nutshell. *Current opinion in genetics & development*, 75:101924, 2022.

[10] Yuanyuan An and Hua Duan. The role of m6a rna methylation in cancer metabolism. *Molecular cancer*, 21(1):14, 2022.

[11] Liuer He, Huiyu Li, Anqi Wu, Yulong Peng, Guang Shu, and Gang Yin. Functions of n6-methyladenosine and its role in cancer. *Molecular cancer*, 18:1–15, 2019.

[12] The role of m 6 a rna methylatio.

[13] Boxuan Simen Zhao, Sigrid Nachtergaele, Ian A Roundtree, and Chuan He. Our views of dynamic n6-methyladenosine rna methylation. *Rna*, 24(3):268–272, 2018.

[14] Xiaoli Qiang, Huangrong Chen, Xiucai Ye, Ran Su, and Leyi Wei. M6amrfs: robust prediction of n6-methyladenosine sites with sequence-based features in multiple species. *Frontiers in genetics*, 9:495, 2018.

[15] Nigel P Mongan, Richard D Emes, and Nathan Archer. Detection and analysis of rna methylation. *F1000Research*, 8:F1000–Faculty, 2019.

[16] Roland Jacob, Sindy Zander, and Tony Gutschner. The dark side of the epitranscriptome: chemical modifications in long non-coding rnas. *International Journal of Molecular Sciences*, 18(11):2387, 2017.

[17] Kevin Tsai and Bryan R Cullen. Epigenetic and epitranscriptomic regulation of viral replication. *Nature Reviews Microbiology*, 18(10):559–570, 2020.

[18] Suresh Kumar and Trilochan Mohapatra. Deciphering epitranscriptome: modification of mrna bases provides a new perspective for post-transcriptional regulation of gene expression. *Frontiers in cell and developmental biology*, 9:628415, 2021.

[19] Ghada Mubarak and Farah R Zahir. Recent major transcriptomics and epitranscriptomics contributions toward personalized and precision medicine. *Journal of Personalized Medicine*, 12(2):199, 2022.

[20] Jose M Herranz, Amaya López-Pascual, Alex Clavería-Cabello, Iker Uriarte, M Ujúe Latasa, Ainara Irigaray-Miramon, Elena Adán-Villaescusa, Borja Castelló-Uribe, Bruno Sangro, María Arechederra, et al. Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human nafld. *Journal of physiology and biochemistry*, 79(4):901–924, 2023.

[21] Elizabeth L Lieu, Tu Nguyen, Shawn Rhyne, and Jiyeon Kim. Amino acids in cancer. *Experimental & molecular medicine*, 52(1):15–30, 2020.

[22] Pedro Morais, Hironori Adachi, and Yi-Tao Yu. Spliceosomal snrna epitranscriptomics. *Frontiers in genetics*, 12:652129, 2021.

[23] Ian A Roundtree, Guan-Zheng Luo, Zijie Zhang, Xiao Wang, Tao Zhou, Yiquang Cui, Jiahao Sha, Xingxu Huang, Laura Guerrero, Phil Xie, et al. Ythdc1 mediates nuclear export of n6-methyladenosine methylated mrnas. *elife*, 6:e31311, 2017.

[24] Valerio Piomponi, Miroslav Krepl, Jiri Sponer, and Giovanni Bussi. Molecular simulations to investigate the impact of n6-methylation in rna recognition: Improving accuracy and precision of binding free energy prediction, 2024.

[25] Elzbieta Kierzek, Xiaoju Zhang, Richard M Watson, Scott D Kennedy, Marta Szabat, Ryszard Kierzek, and David H Mathews. Secondary structure prediction for rna sequences including n6-methyladenosine. *Nature communications*, 13(1):1271, 2022.

[26] Sha Wu, Xiao-Feng Li, Yuan-Yuan Wu, Su-Qin Yin, Cheng Huang, and Jun Li. N6-methyladenosine and rheumatoid arthritis: a comprehensive review. *Frontiers in immunology*, 12:731842, 2021.

[27] Jianzhong Hu, Stefano Manduzio, and Hunseung Kang. Epitranscriptomic rna methylation in plant development and abiotic stress responses. *Frontiers in Plant Science*, 10:500, 2019.

[28] Jiayao Yu, Yi Li, Tian Wang, and Xiang Zhong. Modification of n6-methyladenosine rna methylation on heat shock protein expression. *PloS one*, 13(6):e0198604, 2018.

[29] Chen Xue, Qingfei Chu, Qiuxian Zheng, Shiman Jiang, Zhengyi Bao, Yuanshuai Su, Juan Lu, and Lanjuan Li. Role of main rna modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. *Signal transduction and targeted therapy*, 7(1):142, 2022.

[30] Brandon Tan, Hui Liu, Songyao Zhang, Suzane Ramos Da Silva, Lin Zhang, Jia Meng, Xiaodong Cui, Hongfeng Yuan, Océane Sorel, Shao-Wu Zhang, et al. Viral and cellular n6-methyladenosine and n6, 2-o-dimethyladenosine epitranscriptomes in the kshv life cycle. *Nature microbiology*, 3(1):108–120, 2018.

[31] Marina Tusup, Thomas Kundig, and Steve Pascolo. Epitranscriptomics of cancer. *World journal of clinical oncology*, 9(3):42, 2018.

[32] Michael J McFadden and Stacy M Horner. N6-methyladenosine regulates host responses to viral infection. *Trends in biochemical sciences*, 46(5):366–377, 2021.

[33] Phillip J Hsu, Yunfei Zhu, Honghui Ma, Yueshuai Guo, Xiaodan Shi, Yuanyuan Liu, Meijie Qi, Zhike Lu, Hailing Shi, Jianying Wang, et al. Ythdc2 is an n6-methyladenosine binding protein that regulates mammalian spermatogenesis. *Cell research*, 27(9):1115–1127, 2017.

[34] Lin Chen, Yang Gao, Simiao Xu, Jinxiong Yuan, Min Wang, Tianyu Li, and Jun Gong. N6-methyladenosine reader ythdf family in biological processes: structures, roles, and mechanisms. *Frontiers in Immunology*, 14:1162607, 2023.

[35] Dongjun Dai, Hanying Wang, Liyuan Zhu, Hongchuan Jin, and Xian Wang. N6-methyladenosine links rna metabolism to cancer progression. *Cell death & disease*, 9(2):124, 2018.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.